Important Information for Intellia Therapeutics Investors: Securities Class Action Lawsuit Filed
New York, NY – March 21, 2025
Background
Levi & Korsinsky, LLP, a leading securities litigation firm, has announced that a class action securities lawsuit has been commenced on behalf of investors in Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA). The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024, and January 8, 2025.
Details of the Lawsuit
The complaint alleges that Intellia made false and misleading statements and failed to disclose material information to the investing public throughout the Class Period. Specifically, the complaint alleges that the Company made false and/or misleading statements and/or failed to disclose:
- That the Company’s CRISPR/Cas9 gene-editing technology was not progressing as rapidly as represented;
- That the Company was experiencing manufacturing issues with its CRISPR/Cas9 technology;
- That the Company’s collaboration with Regeneron Pharmaceuticals, Inc. was not progressing as expected;
- That the Company’s financial results would be negatively impacted.
Impact on Individual Investors
If you invested in Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024, and January 8, 2025, you may be entitled to recover your losses, including out-of-pocket transaction costs. The deadline to seek lead plaintiff status is May 23, 2025.
Impact on the World
The securities lawsuit against Intellia Therapeutics could have far-reaching implications for the gene-editing industry as a whole. The allegations of misrepresentation and failure to disclose could damage investor confidence in the sector and potentially slow down the pace of research and development. It could also lead to increased regulatory scrutiny of companies in the space. However, it’s important to note that the allegations are just that – allegations – and the case is still in its early stages.
Conclusion
The securities lawsuit against Intellia Therapeutics is an important development for investors in the gene-editing sector. If you invested in Intellia between July 30, 2024, and January 8, 2025, and believe that you have suffered losses as a result of the Company’s alleged misrepresentations, you may be entitled to recover your losses. It’s important to stay informed about the progress of the case and your options as an investor. For more information, contact Levi & Korsinsky, LLP.
The impact of the lawsuit on the gene-editing industry as a whole remains to be seen. However, it’s clear that the allegations could have significant implications for investor confidence and regulatory oversight in the sector. As always, it’s important to do your due diligence before making any investment decisions.
